Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Citation

  • Authors: She M. et al.
  • Year: 2022
  • Journal: FASEB J 36 e22289
  • Applications: in vitro / DNA / jetOPTIMUS
  • Cell type: Primary scleral fibroblasts

Method

Cells were seeded for 24 h before transfection to reach 80% confluence at the time of transfection. Vector (pEX-3) and AREG-targeted plasmid DNA (synthesized by GenePharma, Shanghai, China) were transfected using jetOPTIMUS in vitro DNA transfection reagent (Polyplustransfection SA, France). A total of 2 μg of DNA was transfected into each well.

Abstract

Previous studies have found that amphiregulin (AREG) may participate in eye elongation during the development of myopia, but the mechanism remains unclear. Here, we tested tear concentrations of AREG in adults and detected the role of AREG in scleral remodeling in form-deprivation myopia (FDM) in guinea pigs. We found the tear concentrations of AREG in myopes were significantly higher than those in emmetropes using enzyme-linked immunosorbent assay (ELISA). Tear concentrations of AREG were negatively correlated with spherical equivalent refraction and positively correlated with axial length (AL) and AL/corneal radii. We then used RNAi, DNA transfection and PD98059 treatments to determine the effects of AREG on extracellular signal-regulated kinase 1/2 (ERK1/2) and matrix metalloprotease-2 (MMP-2) in primary scleral fibroblasts (SFs). The hypothesis was further verified via loss- and gain-of-function experiments by intravitreal application of anti-AREG antibody (anti-AR) or AREG in form-deprivation eyes in guinea pigs. Immunofluorescence assay was used for cell type identification. Western-blot and q-PCR were used for the detection of relative expressions. Transmission electron microscopy was performed for posterior scleral observation. In vitro, we found AREG overexpression increased phospho-ERK1/2 and MMP-2 expression, while depletion of AREG inhibited their expressions. PD98059 (an effective ERK1/2 inhibitor) inhibited AREG-induced MMP-2 upregulation. In vivo, we found anti-AR treatments suppressed FDM by inhibiting scleral remodeling, while AREG treatments promoted FDM. Our results suggest that AREG in tear fluids can serve as a potential biomarker in myopes. AREG is involved in scleral remodeling through the ERK1/2-MMP-2 pathway. AREG is a potential target for myopia control.

Go to